NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

INO

Inovio Pharmaceuticals Inc

Jul 01 • 04:00PM ET

2.04

Dollar change +0.00
Percentage change 0.25	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NVAX PFE BNTX GSK JNJ AZN VXRT ARCT ADMA

| Held by: VTI VXF VTWO IWC IWM AVSC IWN VTWV MSSM DFAT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.19	Insider Own	0.79%	Shs Outstand	36.67M	Perf Week	-0.97%
Market Cap	74.81M	Forward P/E	-	EPS next Y	-1.79	Insider Trans	0.00%	Shs Float	36.39M	Perf Month	2.00%
Enterprise Value	17.72M	PEG	-	EPS next Q	-0.62	Inst Own	37.18%	Short Float	17.75%	Perf Quarter	25.15%
Income	-96.48M	P/S	267.19	EPS this Y	47.65%	Inst Trans	2.54%	Short Ratio	9.25	Perf Half Y	9.68%
Sales	0.28M	P/B	1.46	EPS next Y	13.35%	ROA	-89.17%	Short Interest	6.46M	Perf YTD	11.48%
Book/sh	1.40	P/C	1.09	EPS next 5Y	39.23%	ROE	-132.44%	52W High	12.33 -83.45%	Perf Year	-73.71%
Cash/sh	1.86	P/FCF	-	EPS past 3/5Y	39.06% 22.92%	ROIC	-160.94%	52W Low	1.42 43.66%	Perf 3Y	-91.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-50.31% -44.44%	Gross Margin	-999.88%	Volatility	9.15% 7.04%	Perf 5Y	-99.29%
Dividend TTM	-	EV/Sales	63.30	EPS Y/Y TTM	42.41%	Oper. Margin	-37430.19%	ATR (14)	0.15	Perf 10Y	-98.13%
Dividend Ex-Date	-	Quick Ratio	2.63	Sales Y/Y TTM	-60.52%	Profit Margin	-34079.58%	RSI (14)	49.44	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	2.63	EPS Q/Q	61.02%	SMA20	-2.38%	Beta	1.32	Target Price	8.00
Payout	-	Debt/Eq	0.22	Sales Q/Q	-	SMA50	2.28%	Rel Volume	1.22	Prev Close	2.04
Employees	134	LT Debt/Eq	0.17	Earnings	May 13 AMC	SMA200	-32.67%	Avg Volume	698.67K	Price	2.04
IPO	Dec 08, 1998	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.30% 422.40%	Trades		Volume	852,748	Change	0.25%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Initiated	Stephens	Overweight	$20
Jan-25-24	Upgrade	Oppenheimer	Perform → Outperform	$4
Nov-09-22	Downgrade	Maxim Group	Buy → Hold
Nov-01-22	Downgrade	BofA Securities	Neutral → Underperform	$2
Jul-19-22	Resumed	RBC Capital Mkts	Sector Perform	$5 → $4
May-11-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-21-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $10
Dec-29-21	Resumed	Jefferies	Hold	$8 → $6
Sep-10-21	Downgrade	BofA Securities	Neutral → Underperform	$9 → $8
Jun-24-21	Initiated	Jefferies	Hold	$9
Mar-23-21	Initiated	BofA Securities	Neutral	$13
Feb-12-21	Initiated	Oppenheimer	Outperform	$35
Nov-17-20	Downgrade	ROTH Capital	Neutral → Sell
Nov-10-20	Upgrade	ROTH Capital	Sell → Neutral	$8
Sep-28-20	Upgrade	Maxim Group	Hold → Buy	$20
Sep-28-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-01-20	Downgrade	ROTH Capital	Neutral → Sell	$11
Jul-01-20	Downgrade	Maxim Group	Buy → Hold
Jun-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-26-20	Downgrade	Stifel	Buy → Hold	$19 → $24

Show Previous Ratings

Today 07:00AM	Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development (GlobeNewswire)
May-14-25 12:43PM	Q1 2025 Inovio Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings Call Highlights: Strategic Cost Management ... (GuruFocus.com)
May-13-25 05:40PM	Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:39PM	Inovio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Apr-30-25 08:05AM	INOVIO to Present at Upcoming Scientific and Investor Conferences (PR Newswire)
Apr-29-25 08:05AM	INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 (PR Newswire)
Apr-21-25 07:40AM	Bet on These 5 Top-Ranked Stocks With Rising P/E (Zacks)
Apr-09-25 12:00PM	Inovio (INO) Upgraded to Buy: Here's What You Should Know (Zacks) +8.90%
08:05AM	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
Apr-01-25 09:35AM	Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) (Zacks) -7.98%
Mar-19-25 03:02AM	Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -6.67%
Mar-18-25 10:15PM	Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript (Motley Fool)
04:05PM	INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (PR Newswire)
06:15PM	Loading…
Mar-13-25 06:15PM	INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 (PR Newswire) -5.85% +5.18%
Mar-12-25 12:55PM	INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 (PR Newswire) +5.13%
Feb-12-25 09:55AM	Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher (Zacks) +12.11%
08:00AM	Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications (PR Newswire)
Feb-10-25 08:05AM	Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference (PR Newswire)
Jan-29-25 04:14PM	INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire) -7.31%
Jan-09-25 08:04AM	INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments (PR Newswire)
Dec-13-24 07:00AM	INOVIO Announces Pricing of $30 Million Public Offering (PR Newswire) -38.30%
Dec-12-24 04:01PM	INOVIO Announces Proposed Public Offering (PR Newswire) -6.58%
Dec-03-24 08:00AM	New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial (PR Newswire)
Nov-29-24 04:02PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Nov-15-24 02:15AM	Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ... (GuruFocus.com) -10.59%
02:08AM	Where are they now? 4 biotechs that soared then crashed during the pandemic (Pharma Voice)
Nov-14-24 09:15PM	Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript (Motley Fool)
04:27PM	Inovio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Nov-13-24 08:00AM	Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial (PR Newswire)
Nov-06-24 04:05PM	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
08:00AM	INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024 (PR Newswire)
Oct-21-24 08:00AM	INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP (PR Newswire)
Oct-09-24 05:38AM	Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Oct-02-24 04:15PM	INOVIO Reports Inducement Grants Under Inducement Plan (PR Newswire)
Oct-01-24 08:00AM	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
Sep-17-24 04:30PM	INOVIO to Present at Upcoming Scientific Conference (PR Newswire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-09-24 02:30AM	Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-08-24 04:40PM	Inovio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
Aug-01-24 04:05PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire) -6.00% -5.29%
Jul-25-24 04:05PM	Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 (PR Newswire)
08:00AM	INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 (PR Newswire)
Jul-12-24 10:09AM	Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK (Zacks)
09:28AM	Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-24 08:00AM	INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway (PR Newswire) +18.97%
Jul-02-24 04:05PM	INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer (PR Newswire)
Jul-01-24 04:00PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire) +6.56%
08:00AM	INOVIO Added to Russell 2000 Index Effective July 1, 2024 (PR Newswire)
Jun-04-24 08:00AM	INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. (PR Newswire)
May-31-24 04:48PM	INOVIO Reports Inducement Grants Under Inducement Plan (PR Newswire)
May-22-24 09:45AM	Better Buy: Inovio Pharmaceuticals vs. Novavax (Motley Fool)
May-14-24 08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:55AM	Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target (MT Newswires)
03:02AM	Inovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 09:45PM	Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript (Motley Fool) +6.67%
08:55PM	INO Stock Earnings: Inovio Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
04:28PM	Inovio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
May-05-24 08:54AM	This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy? (Motley Fool)
May-01-24 08:00AM	INOVIO Reports Inducement Grants Under Inducement Plan (PR Newswire)
Apr-29-24 08:00AM	INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 (PR Newswire) +8.80%
08:00AM	INOVIO to Participate in Upcoming Investor Conferences in May (PR Newswire)
Apr-15-24 06:39PM	INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (PR Newswire) -12.33%
Mar-26-24 06:28PM	INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine (PR Newswire) +5.25%
Mar-08-24 09:55AM	Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect? (Zacks) +12.74%
Mar-07-24 10:38AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.51%
06:39AM	Q4 2023 Inovio Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-06-24 11:30PM	Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript (Motley Fool)
09:54PM	INO Stock Earnings: Inovio Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (PR Newswire)
07:00AM	Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Feb-21-24 09:55AM	Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know (Zacks)
08:00AM	INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 (PR Newswire)
Feb-12-24 06:25AM	Inovio (INO) Moves 17.4% Higher: Will This Strength Last? (Zacks) +5.64%
Feb-07-24 11:46AM	INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Feb-02-24 08:00AM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire) -5.08%
Jan-30-24 09:55AM	How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72% (Zacks) -6.25%
Jan-24-24 09:13AM	Why Is Inovio Pharmaceuticals (INO) Stock Down Today? (InvestorPlace)
Jan-23-24 08:00AM	INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split (PR Newswire) -16.15%
Jan-22-24 08:00AM	INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader (PR Newswire)
Jan-12-24 09:43AM	Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why (Zacks) -12.99%
Jan-04-24 08:00AM	INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI (toripalimab-tpzi) (PR Newswire) +9.97%
Jan-03-24 08:00AM	INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program (PR Newswire) -7.70%
Nov-14-23 10:56AM	The 3 Most Undervalued Biotech Stocks to Buy: November 2023 (InvestorPlace) +7.14%
Nov-10-23 03:38PM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:00AM	Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-09-23 04:42PM	Inovio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights (PR Newswire)
Nov-01-23 08:00AM	INOVIO Reports Inducement Grants Under Inducement Plan (PR Newswire)
Oct-26-23 08:00AM	INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023 (PR Newswire)
Oct-19-23 09:53AM	Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why (Zacks)
Oct-10-23 08:00AM	INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program (PR Newswire) +41.00%
Sep-28-23 11:10AM	Inovio spinoff Geneos raises another $5M to advance therapeutic cancer vaccines (American City Business Journals)
Sep-27-23 07:39PM	Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million (PR Newswire)
Sep-07-23 08:00AM	INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Sep-06-23 09:31PM	Philadelphia-area life sciences firms have now cut more than 500 jobs since the start of 2022 (American City Business Journals) -5.52%

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INO

Inovio Pharmaceuticals Inc

Upgrade your FINVIZ experience